Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells

International Journal of Cancer

Volumn 125, Issue 2, 2009, Pages 276-285

  Chipitsyna, Galina ^a   Gong, Qiaoke ^a   Anandanadesan, Rathai ^a   Alnajar, Amer ^a   Batra, Surinder K ^b   Wittel, Uwe A ^b   Cullen, Diane M ^c   Akhter, Mohammed P ^c   Denhardt, David T ^d   Yeo, Charles J ^a   Arafat, Hwyda A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Cigarette smoke; Nicotine; Osteopontin; Pancreatic cancer

Indexed keywords

GENISTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER TISSUE; CARCINOMA CELL; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL; UPREGULATION; ANIMAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NICOTINE; OSTEOPONTIN; PANCREATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMOKE;

EID: 67449102223     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24388     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008;8:212-26.
3. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
4. Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, Denhardt DT. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005;22:663-73.
5. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007;1:81-90.
6. Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994;9:2321-6.
7. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-6.
8. Sedivy R, Peters K, Kl€oppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005;446:41-5.
9. Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, Iacobuzio-Donahue CA, Adsay V, Ashfaq R, Yeo CJ, Cameron JL, Offerhaus JA, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004;3:651-6.
10. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91.
11. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem 2005;95:649-56.
12. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:197-209.
13. Mack TM, Yu MC, Hanisch R, Henderson BE. Pancreas cancer and smoking, beverage consumption and past medical history. J Natl Cancer Inst 1986;76:49-60.
14. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and use of tobacco, alcohol and coffee. J Natl Cancer Inst 1986;76:49-60.
15. Silverman DT, Dunn JA, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, Brown LM, Greenberg RS, Hayes RB, Swanson GM, Wacholder S, Schwartz AG, et al. Cigarette smoking and pancreas cancer: a case control study based on direct interviews. J Natl Cancer Inst 1986;86:1510-6.
16. Miller BA, Silverman DT, Kaplan R. Pancreas. In: Miller BA, Ries HAG, Hankey BF, Kosary CL, Harras A, Devesa SS, Edwards BK, editors. SEER cancer statistics review: 1973-1990. Bethesda, MD: NIH Publication, NCI, 1993.2789-93.
17. Miller NS. Nicotine addiction as a disease. In: Cocores JA, editor. The clinical management of nicotine dependence. New York: Springer-Verlag, 1991.66-78.
18. Surgeon General. The health consequences of using smokeless tobacco. USPHS, Bethesda, MD, NIH Publication #86-2874, 1986.
19. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and risk of pancreatic cancer. The international pancreatic study group. N Engl J Med 1993;328:1433-7.
20. Mack TM, Yu MC, Hanisch R, Henderson BE. Pancreas cancer and smoking, beverage consumption and past medical history. J Natl Cancer Inst 1986;76:49-60.
21. Gold EB, Cameron JL. Chronic pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;323:1485-1486.
22. Chowdhury P, Rayford PL, Chang LW. Inductions of pancreatic acinar cell pathology via inhalation of nicotine. Proc Soc Exp Biol Med 1992;20:159-64.
23. Chowdhury P, Hosotani R, Chang L, Rayford PL. Metabolic and pathologic effects of nicotine on the gastrointestinal tract and pancreas of rats. Pancreas 1990;5:222-9.
24. Dubick MA, Palmer R, Lau PP, Morril PR, Geokas MC. Altered exocrine pancreatic function in rats treated with nicotine. Toxicol Appl Pharmacol 1988;96:132-9.
25. Chowdhury P, Doi R, Tangoku A, Rayford PL. Structure and functional changes of rat exocrine pancreas exposed to nicotine. Int J Pancreatol 1995;18:257-64.
26. Chipitsyna G, Gong Q, Gray CF, Arafat HA. Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells. Endocrinology 2007;148:2198-208.
27. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000;3:624-8.
28. Asaumi S, Takemoto M, Yokote K, Ridall AL, Butler WT, Fujimoto M, Kobayashi K, Kawamura H, Take A, Saito Y, Mori S. Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. J Diabetes Complications 2003;17:34-8.
29. Bose C, Zhang H, Udupa KB, Chowdhury P Activation of p-ERK1/2 by nicotine in pancreatic tumor cell line AR42J: effects on proliferation and secretion. Am J Physiol Gastrointest Liver Physiol 2005;289:G926-34.
30. Chowdhury P, Bose C, Udupa KB. Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signalling and function. Cell Prolif 2007;40:125-41.
31. Wittel UA, Pandey KK, Andrianifahanana M, Johansson SL, Cullen DM, Akhter MP, Brand RE, Prokopczyk B, Batra SK. Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol 2006;101:148-59.
32. Moffett J, Kratz E, Stachowiak MK. Increased tyrosine phosphorylation and novel cis-acting element mediate activation of the fibroblast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor. New mechanism for trans-synaptic regulation of cellular development and plasticity. Brain Res Mol Brain Res 1998;55:293-305.
33. Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 2006;6:401-7.
34. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-8.
35. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J. 2006;20:2093-101.
36. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000;22:818-26.
37. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
38. Chu M, Guo J, Chen CY. Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem 2005;280:6369-79.
39. Wada T, Naito M, Kenmochi H, Tsuneki H, Sasaoka T. Chronic nicotine exposure enhances insulin-induced mitogenic signaling via upregulation of alpha7 nicotinic receptors in isolated rat aortic smooth muscle cells. Endocrinology 2007;148:790-9.
40. Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG. Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol 2006;4:831-6.
41. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992;258:478-80.
42. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995;270:14843-6.
43. Katakam AK, Chipitsyna G, Gong Q, Gabbeta J, Dafoe DC, Arafat HA. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J Endocrinol 2005;18:237-47.
44. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3- kinase/Akt signaling pathway. J Biol Chem 2001;276:46024-30.
45. Tuck AB, Hota C Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001;70:197-204.
46. Mi Z, Guo H, Wai PY, Gao C Kuo PC. Integrin linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006;27:1134-45.
47. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008;68:152-61.
48. Tuck AB, Hota C, Wilson SM, Chambers AF. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003;22:1198-1205.
49. Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 2006;40:132-40.